Home Healthcare Pharmaceuticals Stomach Cancer Market

Stomach Cancer Market Size, Share & Trends Analysis Report By Type (Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Others), By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery), By End-User (Ambulatory Surgery Centers, Hospitals and Specialty Clinics, Other End-Users) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: July 30, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Stomach Cancer Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Adenocarcinoma
    2. Lymphoma
    3. Gastrointestinal Stromal Tumor
    4. Carcinoid Tumor
    5. Others
  2. Stomach Cancer Market, By Therapy Type 2022-2034 (USD MILLION/ Units)
    1. Chemotherapy 
    2. Targeted Therapy 
    3. Immunotherapy 
    4. Radiation Therapy 
    5. Surgery 
  3. Stomach Cancer Market, By End-User 2022-2034 (USD MILLION/ Units)
    1. Ambulatory Surgery Centers 
    2. Hospitals and Specialty Clinics 
    3. Other End-Users
  4. Regional Stomach Cancer Market
    1. North America
      1. North America Stomach Cancer Market By Type 2022-2034 (USD MILLION/ Units)
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
      2. North America Stomach Cancer Market By Therapy Type 2022-2034 (USD MILLION/ Units)
        1. Chemotherapy 
        2. Targeted Therapy 
        3. Immunotherapy 
        4. Radiation Therapy 
        5. Surgery 
      3. North America Stomach Cancer Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Ambulatory Surgery Centers 
        2. Hospitals and Specialty Clinics 
        3. Other End-Users
      4. U.S.
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      5. Canada
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
    2. Europe
      1. Europe Stomach Cancer Market By Type 2022-2034 (USD MILLION/ Units)
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
      2. Europe Stomach Cancer Market By Therapy Type 2022-2034 (USD MILLION/ Units)
        1. Chemotherapy 
        2. Targeted Therapy 
        3. Immunotherapy 
        4. Radiation Therapy 
        5. Surgery 
      3. Europe Stomach Cancer Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Ambulatory Surgery Centers 
        2. Hospitals and Specialty Clinics 
        3. Other End-Users
      4. U.K.
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      5. Germany
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      6. France
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      7. Spain
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      8. Italy
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      9. Russia
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      10. Nordic
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      11. Benelux
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      12. Rest of Europe
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
    3. APAC
      1. APAC Stomach Cancer Market By Type 2022-2034 (USD MILLION/ Units)
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
      2. APAC Stomach Cancer Market By Therapy Type 2022-2034 (USD MILLION/ Units)
        1. Chemotherapy 
        2. Targeted Therapy 
        3. Immunotherapy 
        4. Radiation Therapy 
        5. Surgery 
      3. APAC Stomach Cancer Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Ambulatory Surgery Centers 
        2. Hospitals and Specialty Clinics 
        3. Other End-Users
      4. China
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      5. Korea
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      6. Japan
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      7. India
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      8. Australia
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      9. Singapore
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      10. Taiwan
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      11. South East Asia
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      12. Rest of Asia-Pacific
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
    4. Middle East and Africa
      1. Middle East and Africa Stomach Cancer Market By Type 2022-2034 (USD MILLION/ Units)
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
      2. Middle East and Africa Stomach Cancer Market By Therapy Type 2022-2034 (USD MILLION/ Units)
        1. Chemotherapy 
        2. Targeted Therapy 
        3. Immunotherapy 
        4. Radiation Therapy 
        5. Surgery 
      3. Middle East and Africa Stomach Cancer Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Ambulatory Surgery Centers 
        2. Hospitals and Specialty Clinics 
        3. Other End-Users
      4. UAE
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      5. Turkey
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      6. Saudi Arabia
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      7. South Africa
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      8. Egypt
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      9. Nigeria
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      10. Rest of MEA
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
    5. LATAM
      1. LATAM Stomach Cancer Market By Type 2022-2034 (USD MILLION/ Units)
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
      2. LATAM Stomach Cancer Market By Therapy Type 2022-2034 (USD MILLION/ Units)
        1. Chemotherapy 
        2. Targeted Therapy 
        3. Immunotherapy 
        4. Radiation Therapy 
        5. Surgery 
      3. LATAM Stomach Cancer Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Ambulatory Surgery Centers 
        2. Hospitals and Specialty Clinics 
        3. Other End-Users
      4. Brazil
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      5. Mexico
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      6. Argentina
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      7. Chile
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      8. Colombia
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
      9. Rest of LATAM
        1. Adenocarcinoma
        2. Lymphoma
        3. Gastrointestinal Stromal Tumor
        4. Carcinoid Tumor
        5. Others
        6. Chemotherapy 
        7. Targeted Therapy 
        8. Immunotherapy 
        9. Radiation Therapy 
        10. Surgery 
        11. Ambulatory Surgery Centers 
        12. Hospitals and Specialty Clinics 
        13. Other End-Users
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.